The PIS signature consisting of 18 genes can accurately predict PFS in ccRCC cases with anti-PD-1 therapy and exhibit significant survival differences between the low-risk group and high-risk group. The gene discussed is PDCD1; the disease is nonpapillary renal cell carcinoma.